{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:09:50Z","timestamp":1792602590304,"version":"4.5.0"},"reference-count":14,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jaad.2024.12.026","type":"journal-article","created":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T11:45:26Z","timestamp":1735299926000},"page":"1024-1031","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["The efficacy of longer-term lebrikizumab treatment in patients with moderate-to-severe atopic dermatitis who did not meet protocol-defined response criteria at week 16 in 2 randomized controlled clinical trials"],"prefix":"10.1016","volume":"92","author":[{"given":"Emma","family":"Guttman-Yassky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Rosmarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein","family":"de Bruin-Weller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Weidinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bieber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Chih-ho","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hany","family":"Elmaraghy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber Reck","family":"Atwater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangeline","family":"Pierce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenjia","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Agell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Garcia Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2024.12.026_bib1","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2147\/CCID.S163814","article-title":"Treatment-resistant atopic dermatitis: challenges and solutions","volume":"12","author":"Johnson","year":"2019","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"10.1016\/j.jaad.2024.12.026_bib2","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1111\/jdv.18345","article-title":"European guideline (EuroGuiDerm) on atopic eczema: part I - systemic therapy","volume":"36","author":"Wollenberg","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2024.12.026_bib3","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2024.12.026_bib4","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/bjd.19574","article-title":"Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)","volume":"184","author":"Wollenberg","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2024.12.026_bib5","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJMoa2206714","article-title":"Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis","volume":"388","author":"Silverberg","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2024.12.026_bib6","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1159\/000512890","article-title":"Successful combination of systemic agents for the treatment of atopic dermatitis resistant to dupilumab therapy","volume":"237","author":"Gori","year":"2021","journal-title":"Dermatology (Basel, Switzerland)"},{"key":"10.1016\/j.jaad.2024.12.026_bib7","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/978-3-319-64804-0_12","article-title":"Adherence in atopic dermatitis","volume":"1027","author":"Patel","year":"2017","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.jaad.2024.12.026_bib8","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1080\/09546634.2016.1174765","article-title":"Addressing treatment challenges in atopic dermatitis with novel topical therapies","volume":"27","author":"Silverberg","year":"2016","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaad.2024.12.026_bib9","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1097\/DER.0000000000000715","article-title":"Financial burden of atopic dermatitis out-of-pocket health care expenses in the United States","volume":"32","author":"Smith Begolka","year":"2021","journal-title":"Dermatitis"},{"key":"10.1016\/j.jaad.2024.12.026_bib10","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s13555-023-00947-7","article-title":"Binding, neutralization and internalization of the interleukin-13 antibody, lebrikizumab","volume":"13","author":"Okragly","year":"2023","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaad.2024.12.026_bib11","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/bjd\/ljad022","article-title":"Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials","volume":"188","author":"Blauvelt","year":"2023","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2024.12.026_bib12","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s13555-021-00643-4","article-title":"Continued treatment with dupilumab is associated with improved efficacy in adults with moderate-to-severe atopic dermatitis not achieving optimal responses with short-term treatment","volume":"12","author":"Armstrong","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaad.2024.12.026_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaci.2018.10.032","article-title":"Atopic dermatitis endotypes and implications for targeted therapeutics","volume":"143","author":"Czarnowicki","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2024.12.026_bib15","first-page":"1712","article-title":"Moderate-to-severe atopic dermatitis patients show increases in serum C-reactive protein levels, correlating with skin disease activity","volume":"6","author":"Vekaria","year":"2017","journal-title":"F1000Res"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962224034145?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962224034145?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T13:13:01Z","timestamp":1762261981000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962224034145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":14,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S0190962224034145"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2024.12.026","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The efficacy of longer-term lebrikizumab treatment in patients with moderate-to-severe atopic dermatitis who did not meet protocol-defined response criteria at week 16 in 2 randomized controlled clinical trials","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2024.12.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}